NEW YORK, Jan. 30, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Banc of California, Inc. (NYSE:BANC) securities between October 29, 2015 and January 20, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/banc-of-california-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including: (1) that the Company had extensive ties to an alleged “fraudster” named Jason Galanis (“Galanis”); (2) that, given Galanis’ history, the Company’s ties to Galanis created substantial regulatory risk; (3) that revelation of Galanis’ ties to the Company could cause a substantial decline in the market price of the Company’s securities; (4) that the Company allegedly misled investors concerning the Company’s connections with Galanis; and (5) that, as a result of the foregoing, Defendants’ positive statements about Banc of California’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Banc of California you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/banc-of-california-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



